Radiographic Sacroiliitis Progression in Psoriatic Arthritis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42384912.
- Also identified by DOI 10.1093/rheumatology/keag336.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess radiographic sacroiliitis progression in psoriatic arthritis (PsA) and factors associated with it. We analyzed a prospective PsA cohort (1978-2025). Pelvic radiographs were obtained biannually. Change (Δ) in the Sacroiliitis Sum Score (SSS, 0-8; left+right modified New York-mNY-grades) was the primary outcome, while patients with SSS = 8 at baseline were excluded from the analyses. Linear mixed-effects models assessed factors associated with ΔSSS over successive clinic visits. As a secondary outcome, time to incident mNY sacroiliitis was evaluated with Cox regression. Among 1,554 eligible patients (median follow-up 6.00 years), 475/1,056 (45%) showed progression in SSS by at least 1 grade. In univariable analyses, male sex, 66-joint swollen count, PASI, nail disease, syndesmophytes, abnormal ESR/CRP and higher DAPSA were associated with progression, while older age and longer PsA duration were associated with less progression. Biologic/targeted synthetic (b/ts) DMARD exposure and follow-up in the post-2011 era were associated with lower progression rates. In multivariable models, older age and b/tsDMARD exposure retained protective associations. Among 831 patients without definite mNY sacroiliitis at baseline and with ≥1 follow-up radiograph, 189 (22.7%) developed definite mNY sacroiliitis. In univariable Cox analysis, nail disease, higher PASI, abnormal ESR/CRP, higher DAPSA, and syndesmophytes were associated with progression, while b/tsDMARD exposure and later eras were associated with lower progression; effects were attenuated after adjustment. Radiographic sacroiliitis progression is common in PsA. Greater inflammatory activity increased risk, whereas b/tsDMARD exposure were protective; progression was lower in the modern treatment era.